Sunitinib in Metastatic Renal Cancer

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Sunitinib is the registered treatment for first-line therapy of metastatic clear-cell carcinoma of the kidney.Data from the Expanded Access Study have shown activity also in non-clear cell renal cancer (NCCRC). The aim of this study is to prospectively evaluate the anti-tumor activity and safety of sunitinib as a first-line therapy in metastatic NCCRC patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Istituto Clinico Humanitas
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Histologically proven diagnosis of metastatic renal cancer with non-clear cell

• No previous treatment

Exclusion Criteria:

• Prior treatment with an antiangiogenetic compound

• Symptomatic and/or unstable pre-existing brain metastases

• Severe or uncontrolled cardiovascular diseases